Marshall Wace North America’s Rocket Pharmaceuticals RCKT Stock Holding History

Marshall Wace North America’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-8,578	Closed	-$470K	–	1728
2020 Q4	$470K	Buy	+8,578	New	+$313K	﹤0.01%	1098
2020 Q3	–	Sell	-61,872	Closed	-$1.3M	–	1429
2020 Q2	$1.3M	Buy	61,872 +55,500	+871%	+$1M	0.01%	693
2020 Q1	$90K	Buy	+6,372	New	+$126K	﹤0.01%	1007
2019 Q3	–	Sell	-11,566	Closed	-$174K	–	1504
2019 Q2	$174K	Sell	11,566 -163,657	-93%	-$2.86M	﹤0.01%	1050
2019 Q1	$3.07M	Buy	+175,223	New	+$2.77M	0.02%	412

Other funds holding RCKT

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

Marshall Wace North America's RCKT Position: Q1 2021 in Review

Marshall Wace North America sold out of Rocket Pharmaceuticals (RCKT) in Q1 2021, closing a stake of 8,578 shares — an estimated $470K sold.

Marshall Wace North America first reported a position in RCKT in Q1 2019 and held it in 5 quarters. The position peaked at $3.07M in Q1 2019. 173 funds tracked by Wall St. Rank hold RCKT as of Q1 2021.

Marshall Wace North America reported no remaining Rocket Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Marshall Wace North America sold 8,578 Rocket Pharmaceuticals shares in Q1 2021, an estimated $470K.
Marshall Wace North America first reported a position in Rocket Pharmaceuticals in Q1 2019 and held it in 5 quarters.
Marshall Wace North America's Rocket Pharmaceuticals position peaked at $3.07M in Q1 2019.
173 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2021.

Based on Marshall Wace North America's 13F filing for Q1 2021, filed 17 May 2021.